Pathway Bioventures — Full Portfolio
18 tracked investments · listed companies and verified rows first
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ajay Shah(Co-founder & CEO)inHenry Tse(Co-founder & Chief Technology Officer)inDino DiCarlo(Director, Promoter)
BoardLindy Fishburne(Director)inJack Fuchs(Director, Promoter)in
Co-investorsAlumni VenturesBasecamp FundBlackhorn VenturesBreakout LabsBreakout VenturesEMV Capital+3 more
Specialist investor in advanced modalities including cell, gene, RNA, and targeted therapies
4BIO Capital is a London-based venture capital firm investing in life sciences, focused on advanced therapies that address high unmet medical and social needs.
BiotechLondon, GB
Afference develops neurotechnology that enables remote sensory perception through wearable devices, allowing people at a distance to share tactile sensations.
AI & Machine LearningDeep TechHardwareHealthtechCleveland, US
Jacob Segil(Co-founder & CEO)inDustin Tyler(Co-founder & CTO)in
BoardTaylor Hurst(Director)inTrevor Zimmerman(Director)in
Co-investorsAnthropy PartnersCWRU Technology VenturesEvolution VC PartnersHannah Grey VenturesJobsOhio VenturesKonvoy Ventures+5 more
Pioneer in RNA editing therapeutics for rare and common diseases
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)Jeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso VenturesLumira VenturesSCI Ventures+6 more
Developing bispecific antibodies for precision autoimmune applications
Co-investorsPfizer Venture Investments
Preclinical-stage company developing next-generation gamma delta T cell engagers for solid and haematological malignancies.
Co-investorsSound Bioventures
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesSound Bioventures
Dimension Bio is a biotechnology company that designs and manufactures regenerative therapeutics using its BioNidum™ platform to restore tissue function lost to disease, trauma, or aging.
BiotechHealthtechNew MaterialsChicago, US
Caralynn Nowinski Collens, M.D.(Co-founder & CEO)Ramille Shah, Ph.D.(Co-founder & CSO)Ramille Shah(Director)Caralynn Collens(Executive Officer, Director)
BoardRima Chakrabarti(Director)in
Co-investorsBetter Ventures Central LlcLofty VenturesPortal InnovationsSolas BioVenturesKdT Ventures
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.
BiotechHealthtechMedical DevicesWest Nyack, US
Marc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology.
BiotechHealthtechGaithersburg, US
Anthony Saleh(Executive Officer)Anthony D. Saleh(CEO)Dave Lemus(COO/CFO)
Co-investorsBrown and White VenturesTachyon Ventures
BiotechNew Haven, US
Ranjit Bindra(Director)Kingson Lin(Cofounder)Kevin L. Rakin(Executive Officer, Director)
BoardLucas de Breed(Director)Kat Kayser-Bricker(Director)
Co-investorsConnecticut InnovationsHighCape Capital
Nionyx develops gene therapies, focusing on the design of viral capsids, expression cassettes, and delivery systems for precision and safety.
BiotechDeep TechHealthtech
Co-investors2048 VenturesACADEMY INVESTORAIN Ventures
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(Founder/CSO)inJack O'Meara(Founding CEO)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaHoxton Ventures+6 more
Scioto Biosciences is a life sciences company with corporate offices and research facilities in Fishers, Indiana.
BiotechDeep TechDigital HealthIndianopolis, US
Joseph Trebley(Executive Officer, Director)James Schulz(Executive Officer, Director)Mark Heiman(Chief Science Officer)inKevin Meyer(Chief Operating Officer)Joe Trebley(Founder & Chief Executive Officer)inJim Schulz(Founder & Chief Financial Officer)in
Co-investorsElevate VenturesIU VenturesMichigan Capital Network
Simergent develops medical device systems for regulated healthcare markets, with expertise in peritoneal dialysis and infusion pump technologies.
BiotechHealthtechMedical DevicesChicago, US
Steve J. Lindo(Co-founder & CEO)Rick Pendergraft(Co-founder & Chief Technology Officer)Dr. James Sloand(Chief Medical Officer)Michael Rohleder(Manager)
Co-investorsAngel Physicians FundPlains Ventures
AIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions.
BiotechHealthtech
Co-investors+ND CapitalARCH Venture PartnersFast Track InitiativeNextech InvestNovalis LifeSciencesOno Venture Investment, Inc.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.